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Marcela M. SATOW(1), Edite H. YAMASHIRO-KANASHIRO(1), Mussya C. ROCHA(1,2), Luiza K. OYAFUSO(4), Rita C. SOLER(4),  
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SUMMARY
This study evaluated the applicability of kDNA-PCR as a prospective routine diagnosis method for American tegumentary 
leishmaniasis (ATL) in patients from the Instituto de Infectologia Emílio Ribas (IIER), a reference center for infectious diseases in São 
Paulo - SP, Brazil. The kDNA-PCR method detected Leishmania DNA in 87.5% (112/128) of the clinically suspected ATL patients, 
while the traditional methods demonstrated the following percentages of positivity: 62.8% (49/78) for the Montenegro skin test, 61.8% 
(47/76) for direct investigation, and 19.3% (22/114) for in vitro culture. The molecular method was able to confirm the disease in 
samples considered negative or inconclusive by traditional laboratory methods, contributing to the final clinical diagnosis and therapy 
of ATL in this hospital. Thus, we strongly recommend the inclusion of kDNA-PCR amplification as an alternative diagnostic method 
for ATL, suggesting a new algorithm routine to be followed to help the diagnosis and treatment of ATL in IIER.
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INTRODUCTION
American tegumentary leishmaniasis (ATL) presents different clinical 
manifestations in Latin America, including mucosal leishmaniasis (ML), 
cutaneous localized leishmaniasis (CL), disseminated leishmaniasis 
(LCD), and diffuse leishmaniasis (DCL). These manifestations are caused 
by seven different species of Leishmania: Leishmania (Leishmania) 
amazonensis, L. (Viannia) braziliensis, L. (V.) guyanensis, L. (V.) 
lainsoni, L. (V.) naiffi, L. (V.) lindenberg, and L. (V.) shawi7,24. Currently, 
the diagnosis of ATL is based mainly on a clinical examination, 
epidemiological data, and complementary laboratory methods, including 
direct investigation (DI), Montenegro skin test (MST), and in vitro 
culture7. Nevertheless, these classical diagnostic methods are often time 
consuming; require an expert in microscopy; have low sensitivity and/
or specificity and can be influenced by the age of infection and quality 
of sampling7. Furthermore, these methods are unable to differentiate 
between the seven species of parasite involved, which can be considered 
an important failure for the disease prognosis and choice of an appropriate 
treatment9,32. VOLPINI et al., 200441 described the potential of a PCR-
RFLP method performed with primers specific for kinetoplast DNA 
(kDNA) of Leishmania genus, followed by HaeIII restriction enzyme 
digestion, for detection of L. (V.) braziliensis in infected DNA samples. 
This species is reported to be the major causative agent of ML in Latin 
America; and it is estimated that 3-5% of CL patients progress to ML form 
when infected with this species7. The specificity of these specific primers 
for the Leishmania genus has been reported in previous studies and no 
cross-reaction was observed for paracoccidioidomycosis, histoplasmosis, 
cutaneous tuberculosis, and candidiasis3, squamous cell carcinoma, 
sporotrichosis, leprosy, lentigo, pyodermitis and vascular ulcer17.
The identification of L. (V.) braziliensis in ATL suspected patients is 
important for elaboration of accurate prognoses and adequate therapy to 
prevent the resurgence of lesions, and the progression of the disease7,24. 
Thus, the aim of this study was to evaluate the applicability of the 
kDNA-PCR followed by restriction enzyme analyze method for routine 
diagnosis of ATL at the IIER
MATERIAL AND METHODS
Patients. The study was conducted on a convenience sample of 128 
patients who attended the Instituto de Infectologia Emílio Ribas (IIER), 
São Paulo, Brazil from March 2007 to January 2012, with clinical signs 
and symptoms compatible with CL or ML. Cutaneous leishmaniasis was 
clinically suspected by the presence of ulcer, while mucosal leishmaniasis 
by the presence of nasal bleeding, drilling nasal septum or infiltrate 
in mucosal7,13,24. The results of the clinical examinations, Montenegro 
skin test, epidemiologic data, and administered drugs were obtained 
by reviewing the medical records. Collected samples from  128 lesions 
were transferred for our lab to be analyzed by Direct Investigation, in 
vitro culture and kDNA PCR.
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The study was approved by the Research Ethics Committee of IIER 
(Process number 326/2009), and by the Research Ethics Committee 
of the Instituto de Medicina Tropical de São Paulo (Process CEP-IMT 
046/2009).
Montenegro skin test (MST). Montenegro skin test was performed 
by Instituto Adolfo Lutz, São Paulo - SP. The technique consists of 
application of 0.5 mL of antigen of L. (L) amazonensis (MHOM/BR/73/
PH8), distributed by the Brazilian Ministry of Health. After 72 h the 
papule was measured using a ruler and the result is expressed in mm. 
It is considered positive if the test is higher than 5 mm10,31. The results 
of the MST were obtained by reviewing the medical records of the 
suspected ATL patients.
Direct investigation (DI). Lesion samples were obtained by biopsy 
after asepsis, and local anesthesia using a 4 mm diameter punch. The 
excess blood was removed from the samples and lesion imprints were 
collected on glass slides. After air drying, the slides were fixed in 
methanol, stained with Giemsa, and microscopically examined by two 
technicians. The results were based on the following criteria: the presence 
of typical Leishmania amastigotes indicated a positive result; the absence 
of amastigotes indicated a negative result; and the presence of atypical 
forms of parasite was considered to suggest a positive result.
In vitro culture and isolation of the parasites. Parts of the lesion 
samples were transferred to a plastic tube with a physiological salt 
solution with 100 U penicillin, 100 mg/mL streptomycin, and 50 µg/mL 
5-fluorocytosine, and forwarded to the Instituto de Medicina Tropical 
(IMT-USP). Each sample was further divided for the in vitro culture 
of parasites and for the DNA extraction procedures. A fraction of the 
sample designated for parasite isolation was incubated in Media 199, 
(SIGMA, USA) with 10% fetal bovine serum at 26 °C in BOD and it 
was examined weekly for a month.
Reference strains. L. (V.) braziliensis (MHOM/BR/75/M2903), 
and L. (L.) amazonensis (IFLA/BR/67/PH8) promastigote forms were 
cultivated in Media 199 with 10% fetal bovine serum at 26 °C in BOD. 
The promastigotes were collected at the exponential growth phase with 
approximately 107 cells per mL (+/- 96 h).
DNA extraction. DNA extraction from tissue lesion samples from 
patients and promastigote reference strains was processed using the 
Wizard Genomic DNA Purification Kit (Promega, USA) following 
the manufacturer’s protocol. The quantification and quality control 
of the DNA extraction procedures were performed using a nano 
spectrophotometer (NanoDrop 1000, Thermo Fisher Scientific). All 
reactions were performed in appropriated places, following the good 
practice of laboratories to avoid sample contamination.
kDNA-PCR: The technique was performed based on the protocol 
described previously41 using the following primers that amplify a 120 
bp fragment of the conserved region of a Leishmania kDNA minicircle: 
kDNA20 forward, 5’- GGG (G/T)AG GGG CGT TCT (G/C)CG AA- 
3’, and kDNA22 reverse, 5’ (G/C)(G/C)(G/C) (A/T)CT AT(A/T) TTA 
CAC CAA CCC C- 3’. The reaction mixtures were prepared in a final 
volume of 20 µL that contained Taq DNA polymerase Buffer with KCl 
(10 mM Tris-HCl pH8.8, 50 mM KCl, and 0.08% (v/v) Nonidet P-40); 
1.0 mM MgCl2; 0.2 mM of each dNTP; 375 pM of each primer; 1 U 
Taq DNA polymerase (recombinant) (Fermentas); and 4 µL (~ 200 ng) 
of DNA. Amplification was conducted using an MWG Biotech Model 
Primus 96 Plus Thermal Cycler with an initial denaturation step at 94 
°C for four min, followed by 35 cycles at 94 °C for one min, 58 °C for 
one min, 72 °C for 30 s, and a final extension step at 72 °C for five min. 
The amplicons were visualized by electrophoresis on 2% agarose gels 
stained with ethidium bromide.
Positive controls that contained the DNA from the reference strains, 
and a negative control with no DNA were included in each reaction set. 
In addition, the samples that were negative according to kDNA-PCR 
protocol were submitted to PCR amplification with primers directed 
to human β-globin PCR1 to verify the quality of the DNA extraction 
procedure.
PCR-RFLP (kDNA- HaeIII): Finally, 10 µL microliters of the 
positive kDNA-PCR products were digested at 37 °C for three hours with 
10 U of HaeIII enzyme (Fermentas), with specific buffer and deionized 
water, total volume of 15 µL, according to the manufacturer’s protocol. 
The restriction fragments were separated on a 10% polyacrylamide gel, 
and stained with ethidium bromide.
RESULTS
Analysis of the results of the traditional diagnosis methods. A 
total of 128 patients with clinically suspected ATL were enrolled in this 
study: 59 (46.1%) patients with a suspicious mucosal lesion (sML), and 
69 (53.9%) patients with suspicious of cutaneous lesions (sCL). As a 
result of problems encountered during the data collection from medical 
records, which were often incomplete lacking important information, 
we were unable to get the results of the three traditional methods for 
routine diagnosis of all 128 patients. Then, tests were analyzed in the 
following frequencies: 89.1% by in vitro culture, 60.9% by MST, and 
59.4% by DI, only kDNA-PCR was performed on all 128 collected 
samples (Table 1). As shown in Table 1, we observed that DI test was 
performed more frequently in sCL patients than for sML patients: 81.2% 
(56/69), and 33.9% (20/59), respectively. On the contrary, MST was 
performed on 71.2% (42/59) of the sML patients, and on 52.2% (36/69) 
of the sCL patients. The results of the DI, MST and in vitro tests were 
analyzed considering only the number of samples truly performed for 
each test (76/128 samples for DI, 78/128 for MST and 114/128 for 
culture (Table 1).
Evaluation of the efficiency of the kDNA-PCR method and 
traditional diagnostic methods. kDNA-PCR was performed on all 
128 collected samples, and amplified Leishmania DNA was observed 
in 112/128 (87.5%) clinically suspected ATL samples (Table 1). The 16 
remaining samples (12.5%) were considered negative after confirmation 
of DNA integrity by human β-globin PCR analysis. In addition, these 
samples were also negative for ATL according to the traditional methods, 
excluding one sample (Table 2).
Thus, we can conclude that kDNA-PCR was the most efficient test, 
with a positivity of 87.5%, followed by the MST with 62.8%, DI with 
61.8%, and in vitro culture with 19.3%. We observed that the efficiency 
of DI, and MST methods was distinct for each clinical manifestation. 
DI test was 1.5 times more efficient for samples from sCL patients, 
than for samples from sML patients. The opposite was observed in the 
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MST results: an efficiency 1.5 times greater for sML patients (73.8% of 
positivity), than for sCL patients (50.0% of positivity).
For DI test and in vitro culture we respectively observed high 
frequencies of suggestive results (25.0%) and, contamination (36.0%) 
indicating the limitations of these techniques. Curiously, in vitro culture 
contamination was 2.9 times more frequent in sML samples (30/55 or 
54.5%) than in sCL samples (11/59 or 18.6%).
As only kDNA-PCR was performed on all collected samples, we 
can compare the efficiency of the three traditional diagnostic methods 
(DI test, MST and in vitro culture) with PCR. We can see in Table 2 
that kDNA-PCR was able to detect the parasite in all samples that were 
positive for the DI test47, and for in vitro culture22. Surprisingly, from 
the 49 samples considered positive after the MST analysis, one was 
negative for kDNA-PCR (it was derived from a patient with chronic ATL 
presenting a recurrent lesion).
Besides that, we verified that the molecular method detected 
Leishmania DNA in 77 samples considered negative or contaminated 
by in vitro culture (41 and 36, respectively), and in the 20 samples 
considered negative or suggestive by the DI test (5 and 15, respectively). 
Interestingly, from the 29 samples considered negative by MST, 25 (or 
86.2%) were positive after kDNA-PCR amplification (17 samples from 
sCL patients, and eight from sML patients - data not shown). From the 
16 samples negative by kDNA-PCR, 15 present the same result when 
performed by traditional methods; just one sample presents different 
results for kDNA-PCR and MST, as discussed above.
The importance of the kDNA-PCR in the clinical practice. We 
divided the 128 DNA samples enrolled in this study into two groups: 
the confirmed ATL patients (CATL), that presented at least one positive 
result for traditional diagnosis tests (DI, MST or in vitro culture); and the 
non-confirmed ATL patients (NCATL), composed by samples with non 
positive results following the same traditional techniques (respectively 
with 83 and 45 DNA samples - Table 3). As expected, kDNA-PCR was 
able to detect parasite DNA in 98.8% of the DNA samples from the CATL 
group (82/83), where the diagnosis had been previously confirmed by a 
combination of the three traditional diagnostic methods. The exception 
was only the patient with chronic ATL with a recurrent lesion, already 
discussed. The importance of the kDNA-PCR amplification in the routine 
diagnosis becomes evident when we analyzed the results of the NCATL 
group. In this group of samples with negative results by the traditional 
diagnostic methods, kDNA-PCR was able to detect the parasite in 66.6% 
(or 30/45).
To better verify the acceptance of the kDNA-PCR results, we 
checked the physician follow-up through the analysis of the medical 
records. Out of 128 samples analyzed, only 92 records presented 
correct data on the conduct adopted by the physician. According to 
Table 1
Results of the four diagnostic methods performed with samples from patients 
with suspected ATL who attended the Instituto de Infectologia Emílio Ribas 
(IIER) in São Paulo, Brazil
Clinical manifestation
Cutaneous Mucosal Total
N (%) N (%) N (%)
Patients 69 53.9% 59 46.1% 128
Direct investigation (76) 
Not performed (52)
Positive 38 67.9% 9 45.0% 47 61.8%
Negative 6 10.7% 4 20.0% 10 13.2%
Suggestive 12 21.4% 7 35.0% 19 25.0%
Total 56 20 76
Montenegro skin test (78)
Not performed (50)
Positive (> 5 mm) 18 50.0% 31 73.8% 49 62.8%
Negative (< 5 mm) 18 50.0% 11 26.2% 29 37.2%
Total 36 42 78
In vitro culture (114)
Not performed (14)
Positive 14 23.7% 8 14.5% 22 19.3%
Negative 34 57.6% 17 30.9% 51 44.7%
Contamination 11 18.6% 30 54.5% 41 36.0%
Total 59 55 114
kDNA-PCR (128)
Positive 61 88.4% 51 86.4% 112 87.5%
Negative 8 11.6% 8 13.6% 16 12.5%
Total 69 59 128
Table 2




In vitro culture DI test MST
P N Cont. P N Sug. P N
Positive 22 (100%) 41 (80.4%) 36 (87.8%) 47 (100%) 5 (50%) 15 (78.9%) 48 (97.9%) 25 (86.2%)
Negative 0 10 (19.6%) 5 (12.2%) 0 5 (50%) 4 (21%) 1 (2%) 4 (13.8%)
kDNA-PCR: Polymerase chain reaction using specific primers for Leihmania’s kinetoplast DNA, DI test: Direct Investigation test, MST: Montenegro skin test. P: 
Positive result, N: Negative result; Sug.: Suggestive, Cont.: contamination. *The same sample could be analyzed by more than one diagnostic method.
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the records, most of these patients, 95.7% (88/92), received specific 
treatment for ATL. Of these 88 treated patients, 18 were positive only 
by kDNA-PCR analysis, 63 presented a positive result in at least one 
of the traditional diagnostic methods (and also positive kDNA-PCR 
positive results), and seven patients were treated based exclusively on 
the clinical examination (when all diagnostic tests, including PCR, 
presented negative or inconclusive results). Interestingly, one of the 
seven treated patients that presented a negative result for kDNA-PCR, 
was later diagnosed as paracoccidioidomycosis, confirming the previous 
PCR result. Contrary, two patients from this same group responded 
clinically well to the ATL drug administration, besides the negative 
results in all diagnosis tests. No information concerning the response 
of treatment about the remaining four treated patients was found in 
the records. Overall, 3/92 patients were not treated even though they 
presented positive kDNA-PCR results (one patient presented positive 
results for both kDNA-PCR and MST). The remaining untreated patient 
was negative by kDNA-PCR analysis.
PCR-RFLP results. To verify the contribution of the PCR-RFLP 
method for identification of L. (V.) braziliensis, HaeIII restriction 
digestion was performed in all 112 amplification products of the 
kDNA-PCR reaction. We verified that 96/112 (or 85.7%) of these 
samples presented the two expected DNA fragments (80 bp and 40 
bp), characteristic of the L. (V.) braziliensis electrophoresis pattern41 
(Fig. 1, lanes 2 to 7). The frequency of L. (V.) braziliensis according to 
the suspected clinical manifestation was 51/61(83.6%) in sCL samples, 
and 45/51(88.23%) in sML samples.
16/112 kDNA-PCR amplification products (10 from sCL samples 
and six from sML samples) did not present the cleavage of the 120 
pb amplification product (Fig. 1, lane 1). Eight samples were from 
patients that have been in endemic regions of L. (L.) amazonensis: five 
from Bahia, one from Maranhão, one from Minas Gerais and one from 
Pernambuco, which can be an evidence of infection caused by this or 
other Leishmania species. One individual reported to have acquired the 
disease in Angola where L. (L.) infantum is the main specie that causes 
leishmaniasis, where specific zymodemes can be related with LC24. Four 
patients have not reported probable local of infection. The remaining three 
individuals indicated São Paulo and Paraná to be the local of infection, 
which are states where L. (V.) braziliensis was the only specie causative 
of human disease. This last result may indicate limitation of the PCR-
RFLP or absence of correct information concerning the probable locals 
of infection.
DISCUSSION
This study evaluated the applicability and efficiency of PCR based on 
kDNA as a routine diagnostic method for ATL, comparing these results 
with the results of tests performed routinely for leishmaniasis diagnosis. 
The data that were obtained indicate that inclusion of the PCR-RFLP 
(kDNA-HaeIII) technique in the routine diagnosis of ATL would improve 
the accuracy of the diagnosis, support an appropriate prognosis, and 
ensure adequate treatment. Moreover, the data indicated that the kDNA-
PCR results are in agreement with the clinical practice performance and 
confirmed the clinical findings (Table 3) that were negative according to 
the traditional methods (Table 2).
The higher efficiency of the kDNA-PCR method over the traditional 
methods for ATL diagnosis (Table 1) observed here is in agreement with 
the literature, which describes sensitivities that range from 75% - 98%, 
and it is attributed to the naturally amplified DNA in the kinetoplast 
minicircle2,4,5,6,14,17,20,30,34,35,40.
Comparative analysis between the sensitivity levels of the methods 
tested here and those from previous studies, was difficult to process due 
to a variety of the techniques and the type of biological samples that were 
used, the inclusion criteria of the samples and the differences among the 
sequences of the kDNA primers34, and the expertise of the technicians. 
Nevertheless, we performed a comparison of the efficiency among the 
kDNA-PCR and traditional methods (Tables 1 and 2) that allowed us to 
evaluate the limitations of each laboratory method.
The in vitro culture presented a lower percentage of positivity and/
or parasite isolation (19.3%, Table 1), than those described by other 
authors, which ranged from 30.3% to 81.5%9,17,18,23. The low sensitivity 
of the in vitro culture test was evidenced in Table 2 were 77 contaminated 
or negative samples by this method were positive by kDNA-PCR. On 
the other hand, these results also indicate that the efficiency of the 
PCR method was not affected by secondary infections, as pointed by 
BOGGILD et al.6.
Concerning the DI test, several studies have demonstrated that the 
quality of the prepared slides, the age of the lesions, the presence of 
Table 3
Number of ATL suspected samples presenting none or at least one positive 










Positive 82 (98.8%) 30 (66.6%) 112
Negative 1 (1.2%) 15 (33.3%) 16
Total 83 45 128
*Positive result for at least one reference method (direct investigation, Montenegro 
skin test or in vitro culture). CATL: ATL DNA samples confirmed by at least one 
of the traditional method(s). NCATL: ATL DNA samples without confirmation 
by traditional method(s).
Fig. 1 - A 10% polyacrylamide gel electrophoresis representing the products of PCR-RFLP 
(kDNA/HaeIII): 1- 7 samples from LTA suspected patients, Lb- DNA from L. (V.) braziliensis 
(positive control).
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secondary microorganisms6,24, and pre-treatment of the lesions can lead 
to atypical forms of the parasite23, resulting in a wide variation in the 
level of sensitivity of the DI tests ranging from 10% to 74.4%3,4,5,11,15,17. 
Corroborating this, we observed that 20 of the 29 samples presenting 
negative or suggestive results by DI test were positive when evaluated 
by kDNA-PCR (Table 2). Eleven of these 20 patients received treatment 
after the positive kDNA-PCR result which confirmed the clinical findings 
and may indicate the acceptance of the kDNA-PCR for diagnosis of ATL 
by the physicians. Thus, we suggest that samples with results that are 
negative or suggestive by DI test require an additional laboratory method, 
as kDNA-PCR to confirm the final diagnosis.
We verified that MST method was more efficient for sML patients 
(73.8% of positivity), than for sCL patients (50% of positivity) (Table 
1). These low positivity rates are in accordance with the literature, which 
reports a range from 51.9%-100% for this test14,16,22,28, and could be a 
consequence of immunosuppression25 or even misinterpretation of the 
result. It is also reported that the sensitivity of the MST can vary with the 
presence of secondary infections6, or the age of the patient15. In our study, 
we also observed that 25 of the 29 samples presenting negative results by 
MST were positive when evaluated by kDNA-PCR amplification (Table 
2). We noted that 17 of these 25 kDNA-PCR positive samples came 
from sCL patients, and eight samples from sML patients, which could 
indicate a recent infection or a weak response from the immune system 
of the patients12,25,29,33. In contrast, one patient that presented positive 
result for MST was considered negative by kDNA-PCR. This ambiguity 
may be due to the fact that the patient had a chronic lesion and few or 
no parasites might be present in the sample subjected to kDNA-PCR 
reaction. As proposed by DA-CRUZ et al.12 the inflammatory lesion, in 
this case, could be due to the activation of T-cells (CD8 +), and not due 
to the presence of parasites. Detection of false-positive MST results was 
also reported in 35% (20 of 57) of the patients with reactions up to 11 
mm in diameter by GOMES et al.22 These patients had negative results 
for in vitro culture, stained tissue smears and PCR for Leishmania’s mini 
exon SL RNA gene. The authors suggested that false-positive results in 
MST could also be result of an allergic process to the antigen diluent, or 
an immune response of patients who are not sick, but have already had 
contact with the parasite in an endemic area22,36.
Therefore, we can infer that the limitation factors that have been 
observed for other laboratory methods, such as contamination by 
secondary microorganisms4,33, the age of infection, cross-reaction to 
antigens or other reagents that are used in antigen production, the intrinsic 
characteristics of the parasite, and the pre-treatment of patients22 does 
not seem to influence the kDNA-PCR results. In addition, the molecular 
method has several advantages: complex procedures are not required to 
collect and to maintain DNA samples for PCR reaction, in contrast to in 
vitro culture and DI test. Complementary, a wide variety of biological 
material can be used as sources of DNA, including material obtained 
by less invasive or non-invasive methods, such as blood28,34, lesion 
impressions on filter paper4,34, scraped, and aspirated lesions6,28, urine40, 
samples fixed in paraffin9 and fixed and stained material from glass 
slides35,37. Despite the promising results of the kDNA-PCR method, 
carry-over contamination must be avoided14, and in our experiments, 
each PCR step was always performed in separate rooms using appropriate 
equipment.
According to our kDNA-HaeIII PCR-RFLP data, 83.6% of sCL 
patients could be infected with L. (V.) braziliensis, suggesting that these 
patients may be at risk of developing the mucosal manifestation or have 
re-activation of lesions, if they do not receive adequate treatment and 
clinical assistance. Although kDNA-HaeIII PCR-RFLP reaction can 
contribute to the identification of L. (V.) braziliensis infected samples, the 
confirmation of the species of the parasite by other molecular methods 
is recommended, once similar electrophoretic patterns may occur within 
related species from Viannia subgenus as reported in other PCR-RFLP 
studies2,38,39.
Studies describing techniques based on PCR for identification of 
the species from Viannia subgenus using DNA of clinical samples have 
been reported such as the Polymorphism-Specific PCR (PS-PCR)26, 
G6PD PCR8, LBF1-LBR1 PCR27. Despite the ability to identify the 
Leishmania’s species, the use of these techniques as routine may not 
be validated since they require high concentration of total DNA27 and 
the employment of several primers for each species8,26. On the contrary, 
the kDNA-HaeIII PCR-RFLP protocol used in our study was simple 
to execute and presented sensibility higher than the traditional routine 
methods.
On the other hand, most of the 128 patients analyzed here are from 
regions where L. (V.) braziliensis is the main causative species responsible 
for the severe manifestation of the disease, which supports the use of 
kDNA-HaeIII PCR-RFLP to assist in posterior clinical practices.
The medical reports review has shown that kDNA-PCR results 
contributed to the treatment of at least 18 patients who had got negative 
results by the traditional methods. The decision to treat these patients 
was also based on the clinical symptoms and epidemiological data, 
confirming that kDNA-PCR is important as a complementary test for 
the diagnosis and treatment of ATL.
Unfortunately, we failed to collect all results of the traditional 
diagnostic tests, as well as the response of the patients’ treatment, 
mainly because the medical records were incomplete or lacked important 
information, which made our comparative analysis difficult (Tables 1, 
and 3). The difficulty in establishing a gold standard method for the 
diagnosis of ATL based on a comparison of diagnostic methods has been 
reported in previous studies22. Moreover, we observed that the results of 
the reference diagnostic methods that were recommended by the National 
Council of Health of the Brazil Ministry of Health (MST for suspected 
ML patients, and DI for suspected CL patients) were not registered in 
the medical records or solicited by the physicians. The same limitations 
were observed in other studies that were conducted in the following states 
of Brazil: Pernambuco36, Mato Grosso33, and Ribeirão Preto, SP19. These 
findings demonstrate that standardization of the tests that are solicited 
for ATL diagnosis, and improvement or modernization of the medical 
records systems in public hospitals in Brazil is needed.
Finally, we strongly recommend the use of the kDNA-PCR to be 
added as routine method for diagnosis of ATL. Patients with suspicion 
of cutaneous lesions (sCL) after the clinical examination, must collect 
biopsies of the border lesion, and send for DI test. Patients with suspicion 
of mucosal lesions (sML) must be submitted for the MST. Patients with 
positive results according to the DI, and/or MST tests must be treated. 
kDNA-PCR can be solicited by the physician in addition to DI/MST or 
performed for disease confirmation when the results of the DI tests, and 
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MST were negative. Patients with positive results for kDNA-PCR can be 
treated. If suspected leishmaniasis patient present negative results for DI 
test, MST and kDNA-PCR ATL could be discharged without treatment. 
The complementary kDNA-HaeIII PCR-RFLP technique can be done 
to help L. (V.) braziliensis identification of infected samples.
RESUMO
Aplicação do kDNA-PCR para diagnóstico de rotina de 
leishmaniose tegumentar americana em um hospital de referência
Este estudo avaliou a aplicabilidade do kDNA-PCR como método de 
rotina para diagnóstico de leishmaniose tegumentar americana (ATL) no 
Instituto de Infectologia Emílio Ribas (IIER), São Paulo, SP, Brasil. O 
método kDNA-PCR detectou DNA de Leishmania em 87,5% (112/128) 
dos pacientes com suspeita de ter leishmaniose e, os métodos tradicionais 
apresentaram as seguintes porcentagens de positividade: 62,8% (49/78) 
para o teste de Montenegro, 61,8% (47/76) para a pesquisa direta e 19,3% 
(22/114) para cultura in vitro. O método molecular confirmou a doença 
em amostras negativas ou inconclusivas pelos métodos laboratoriais 
tradicionais e, mostrou-se capaz de auxiliar na identificação de infecções 
causadas pela espécie Leishmania (V.) braziliensis. Além disso, a revisão 
dos prontuários médicos confirmou a importância do método PCR-RFLP 
no diagnóstico final de ATL, prognóstico e escolha do tratamento. Assim, 
recomendamos a inclusão do PCR como método diagnóstico de ATL na 
rotina hospitalar, e sugerimos um fluxograma para solicitação de exames 
laboratoriais.
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